Universe Pharmaceuticals Statistics
Want to see UPC full AI Analyst Report?
Universe Pharmaceuticals (UPC) Stock Statistics & Valuation Metrics
Total Valuation
Universe Pharmaceuticals has a market cap or net worth of $7.84M. The enterprise value is -$17.95M.
- Market Cap
- $7.84M
- Enterprise Value
- -$17.95M
Share Statistics
Universe Pharmaceuticals has 5,008,313 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 5,008,313
- Owned by Insiders
- 0.32%
- Owned by Institutions
- 0.94%
Financial Efficiency
Universe Pharmaceuticals’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -4.46%.
- Return on Equity (ROE)
- -0.07
- Return on Assets (ROA)
- -0.05
- Return on Invested Capital (ROIC)
- -4.46%
- Return on Capital Employed (ROCE)
- -0.05
- Revenue Per Employee
- 82.68K
- Profits Per Employee
- -17.00K
- Employee Count
- 216
- Asset Turnover
- 0.26
- Inventory Turnover
- 5.27
Valuation Ratios
The current PE Ratio of Universe Pharmaceuticals is -0.41. Universe Pharmaceuticals’s PEG ratio is 0.00.
- PE Ratio
- -0.41
- PS Ratio
- 0.05
- PB Ratio
- 0.01
- Price to FCF
- -0.07
- Price to Operating Cash Flow
- -0.07
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Universe Pharmaceuticals had revenue of 17.86M and earned -3.67M in profits. Earnings per share was -1055.75.
- Revenue
- 17.86M
- Gross Profit
- 6.30M
- Operating Income
- -2.92M
- Pretax Income
- -3.67M
- Net Income
- -3.67M
- EBITDA
- -2.92M
- Earnings Per Share (EPS)
- -1055.75
Cash Flow
In the last 12 months, operating cash flow was -11.91M and capital expenditures -481,018, giving a free cash flow of -12.39M billion.
- Operating Cash Flow
- -11.91M
- Free Cash Flow
- -12.39M
- Free Cash Flow per Share
- -22.00
Dividends & Yields
Universe Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1325.42%
- Earnings Yield
- -232.94%
Stock Price Statistics
- Beta
- 3.44
- 52-Week Price Change
- -57.26%
- 50-Day Moving Average
- 3.54
- 200-Day Moving Average
- 3.67
- Relative Strength Index (RSI)
- 29.32
- Average Volume (3m)
- 151.78K
Important Dates
Universe Pharmaceuticals upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- Aug 03, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Universe Pharmaceuticals as a current ratio of 4.07, with Debt / Equity ratio of 16.49%
- Current Ratio
- 4.07
- Quick Ratio
- 3.90
- Debt to Market Cap
- 633.71
- Net Debt to EBITDA
- 8.33
- Interest Coverage Ratio
- -12.57
Taxes
In the past 12 months, Universe Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Universe Pharmaceuticals EV to EBITDA ratio is 13.08, with an EV/FCF ratio of 1.38.
- EV to Sales
- -0.96
- EV to EBITDA
- 13.08
- EV to Free Cash Flow
- 1.38
- EV to Operating Cash Flow
- 1.43
Balance Sheet
Universe Pharmaceuticals has $29.05M in cash and marketable securities with $9.55M in debt, giving a net cash position of $19.50M billion.
- Cash & Marketable Securities
- $29.05M
- Total Debt
- $9.55M
- Net Cash
- $19.50M
- Net Cash Per Share
- $3.89
- Tangible Book Value Per Share
- $98.23
Margins
Gross margin is 35.86%, with operating margin of -11.78%, and net profit margin of -10.95%.
- Gross Margin
- 35.86%
- Operating Margin
- -11.78%
- Pretax Margin
- -10.95%
- Net Profit Margin
- -10.95%
- EBITDA Margin
- -7.36%
- EBIT Margin
- -10.06%
Analyst Forecast
The average price target for Universe Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -8.04%
- EPS Growth Forecast
- -100.01%
Scores
- Smart Score
- ―
- AI Score
- 41

